P Giraldo

TL;DR: In this study, CML-related deaths were uncommon in CML patients who were in CCyR 2 years after starting imatinib, and survival was not statistically significantly different from that of the general population.

TL;DR: Among all randomly assigned patients with Fabry's disease (with mutant α-galactosidase forms that were suitable or not suitable for migalastat therapy), the percentage of patients who had a response at 6 months did not differ significantly between the migAlastat group and the placebo group.

TL;DR: Among WM and IgM-MGUS, MyD88 L265P mutation was associated with some differences in clinical and biological characteristics, although usually minor; wild-type MYD88 cases had smaller M-component and less IGHV3–23 gene selection; these small differences did not lead to different time to first therapy, response to treatment or progression-free or overall survival.

TL;DR: All patients with type 1 Gaucher disease should undergo comprehensive regular assessment, the frequency of which depends on treatment status and whether therapeutic goals have been achieved, and reassessment should be performed whenever enzyme therapy dose is altered, or in case of significant clinical complication.

TL;DR: An increasing genomic complexity from MGUS to MM and identifies new chromosomal regions involved in CNA and CNN-LOH are shown and a strong association between genetic lesions and fragile sites was detected.